Understanding why patients with serious conditions participate in market research can give us a fresh perspective on sensitive interviewing.
When new products approach the market, the level of demand for them is often exaggerated.
Patient insights aren’t just a nice to have, they are essential to understand the space where Pharma’s drugs ‘live’.
How can we go beyond linear models of customer journey mapping to explore the overall customer experience?
The patient world is multi-dimensional and what may seem irrelevant clinically may be crucial to optimally managing and treating a disease.
Paul Mannu urges HCPs to think about utilising existing technology to enhance their face-to-face meetings with reps, rather than deploying tech for tech's sake
Master Practitioner Paul Mannu reflects on Insight's healthcare technology predictions from January 2015 and, 10 months on, how accurate we proved to be
The fear of unsustainability in healthcare has led to a desire for change. Paul Mannu outlines emerging trends that are framing the future of primary care.
The proliferation of 'clinical segmentation’ presents new challenges for market researchers seeking insight from often very small numbers of patients.
While the focus on antimicrobial resistance intensifies and research into new antibiotics is incentivised, a new blockbuster drug faces many hurdles.
What’s the best way to gain valuable insight from an online qualitative community? Jenny Fletcher shares some principles from our Payer Politics case study.
Pre-election financial sweeteners may lead to selling more product but Pharma must focus on helping the NHS see that money isn’t the solution to its problems.
Please enter your details before proceeding with the download.